Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Simris Alg: Accelerating entry into high-value biopharma with acquisition of Cyano Biotech - Emergers

Simris Group

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
In line with their strategic plan to move into the highest margin application areas, Simris Alg announced an LOI to acquire Cyano Biotech GmbH which would accelerate entry into the BioPharma space. After a production pause to upgrade the facility in Q2’22, Simris expects a pick-up in both biomass and supplements sales in 2023. The additional synergies following a successful merger with Cyano offers both cost savings and new revenue opportunities for BioPharma and ADCs, where each single license deal could add USD 2.1-2.7m to valuation, thereby dominating the business in the long-term.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team